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SummaryA high-calorie diet severely aggravates hepatic mitochondrial and hepatocellular damage in Wilson disease rats. A toxic triad of adenosine triphosphate depletion, increased reactive oxygen species, and increased bile salts lead to an earlier onset of the disease and to enhanced disease progression.

Wilson disease (WD) is an autosomal-recessively inherited disorder of copper metabolism caused by *ATP7B* gene mutations, resulting in impaired biliary copper excretion. Subsequent hepatic copper accumulation induces a heterogeneous phenotype that lacks a clear genotype correlation.[@bib1] Although some individuals remain rather unaffected, others develop mild to moderate chronic liver disease or even acute liver failure.[@bib2] The mechanisms underlying this heterogeneity are currently unknown. Pharmacologic therapies in WD aim to restore copper homeostasis.[@bib2] In *Atp7b*^*-/-*^ rats, an animal model mirroring the WD liver phenotype,[@bib3] hepatic copper accumulation causes a reduced mitochondrial adenosine triphosphate (ATP) production capacity, mitochondrial destruction, liver failure, and animal death.[@bib4], [@bib5] Heterozygous *Atp7b*^*+/-*^ rats do not accumulate copper and thus are highly stringent, nonaffected control animals.[@bib3], [@bib4] Copper-induced mitochondrial damage in *Atp7b*^*-/-*^ rats can be resolved efficiently by innovative treatments using the potent copper chelating agent methanobactin (MB),[@bib5] which has an extraordinarily high copper affinity.[@bib6], [@bib7] MB decreases mitochondrial copper within days, coinciding with liver tissue restoration and avoidance of liver failure and animal death.[@bib5]

Besides mitochondrial impairments, fat accumulation (steatosis) is a frequently observed early characteristic in livers of WD patients.[@bib8], [@bib9] Indeed, WD often may be misdiagnosed as nonalcoholic fatty liver disease (NAFLD).[@bib9] The prevalence of NAFLD is increasing in Western societies, in many cases owing to high-calorie malnutrition (ie, excessive intake of fat and sugar), and the associated metabolic syndrome.[@bib10] Interestingly, in NAFLD patients, mitochondrial alterations similar to those found in WD patients have been reported (eg, altered cristae and reduced ATP production resulting from oxidative phosphorylation defects).[@bib11], [@bib12] Wild-type mice subjected to a high-fat, high-fructose--containing diet have functional deficits in their hepatic mitochondria, most prominently a reduced ATP production capacity.[@bib13], [@bib14] Thus, mitochondrial structural and functional impairments are hallmarks in both WD and NAFLD, suggesting a potential link between aberrant hepatic copper and lipid metabolism.

An obvious dietary recommendation for WD patients is to avoid copper-rich foods (eg, shellfish, nuts, or chocolate) to counteract an excessive hepatic copper accumulation.[@bib15] However, much less attention is given to other aspects of WD patient nutrition[@bib16] (eg, fat or sugar content in their diet). The potential influence of such environmental aspects on WD progression and severity came to our attention by a case report on monozygotic WD twins.[@bib17] One of the twins with nutritional disturbance (bulimia nervosa) had clinically apparent signs of liver failure (eg, ongoing hepatocyte necrosis), and had to undergo liver transplantation. Her twin sister, however, underwent a prolonged period of undernourishment, and presented with asymptomatic mild liver disease.[@bib17] This (and further case reports) suggests that lifestyle may impact WD progression, possibly contributing to differing WD phenotypes and to the conundrum of a lacking genotype--phenotype correlation in WD.[@bib18]

Similar to the clinical situation, in WD research, treatments of relevant animal models have plausibly focused on the amelioration of copper-induced liver damage (eg, with the aim to avoid oxidative liver damage).[@bib19], [@bib20] The opposite, that is, studies on diets that may aggravate disease progression, are virtually nonexistent. Only recently have reports suggested that misbalanced copper homeostasis participates in liver steatosis and may negatively influence not only lipid and cholesterol metabolism, but also the assembly and secretion of lipoproteins from intestinal enterocytes.[@bib21], [@bib22], [@bib23]

Driven by these findings and considerations, we asked whether malnutrition with a high-calorie diet (HCD), enriched in fat and sugar, would influence disease progression in *Atp7b*^*-/-*^ rats. We applied a variant of an HCD that particularly reflects the eating habits in Western society, causing the "American Lifestyle-induced Obesity Syndrome,"[@bib24] and that represents a physiologically relevant, true-to-life-model. The rationale of this study was that both enriched copper and fatty acids cause bioenergetic defects and therefore synergistically and detrimentally may coincide on hepatic mitochondria, which was found to be the case. We thus report here that an HCD accelerated and aggravated liver damage in *Atp7b*^*-/-*^ rats. In comparison with *Atp7b*^*-/-*^ rats fed a normal diet (ND), profoundly increased mitochondrial copper accumulation caused severe bioenergetic defects in HCD-fed *Atp7b*^*-/-*^ rats. We conclude that lipid accumulation in copper-burdened hepatocytes may represent a second hit in WD, inducing liver damage, and suggest that further research should establish whether dietary counseling of WD patients may be of therapeutic benefit.

Results {#sec1}
=======

An HCD Severely Aggravates and Strongly Accelerates Liver Damage in WD Rats {#sec1.1}
---------------------------------------------------------------------------

An HCD significantly increased the visceral fat mass ([Figure 1](#fig1){ref-type="fig"}*A*) and liver triglyceride levels ([Figure 1](#fig1){ref-type="fig"}*B*) within a few weeks of feeding in *Atp7b*^*+/-*^ control rats, compared with their ND-fed counterparts. This coincided with the presence of abundant macrosteatosis in liver histology ([Figure 1](#fig1){ref-type="fig"}*D*) and an increased NAFLD Activity Score (NAS) of 3--5 ([Figure 1](#fig1){ref-type="fig"}*C*, [Table 1](#tbl1){ref-type="table"}). Despite steatosis, however, constant body and liver weights were encountered in the HCD-fed control *Atp7b*^*+/-*^ rats ([Figure 1](#fig1){ref-type="fig"}*E--G*, [Table 2](#tbl2){ref-type="table"}). HCD- vs ND-fed *Atp7b*^*-/-*^ rats (ie, WD rats) also had tendentiously increased visceral fat mass, significantly increased liver triglyceride levels, liver steatosis, and equal body but increased liver weight ([Figures 1](#fig1){ref-type="fig"}*A--G*, [Table 2](#tbl2){ref-type="table"}).Figure 1**An HCD induces liver steatosis in *Atp7b***^***+/-***^**and *Atp7b***^***-/-***^**rats.** (*A--C*) An HCD increases (*A*) visceral fat mass (N = 6--12), (*B*) liver triglyceride content (N = 6--7), and (*C*) NAFLD activity (NAS, N = 6--8) in *Atp7b*^*+/-*^ and *Atp7b*^*-/-*^ rats. (*D*) Liver histology (H&E stain; *scale bar*: 100 μm) from ND-fed vs HCD-fed *Atp7b*^*+/-*^ and *Atp7b*^*-/-*^ rats presents macrosteatosis (*open asterisk*), ballooned hepatocytes (*open arrow*), inflammatory infiltrations (*black arrow*), and some signs of fibrosis (*black asterisk*), apoptosis (*open arrowhead*), or necrosis (*black arrowhead*). (*E* and *F*) Comparable body weights of either male (*E*, N = 2--7) or female (*F*, N = 3--5) ND- or HCD-fed *Atp7b*^*+/-*^ and *Atp7b*^*-/-*^ rats. (*G*) Relative liver weight (% of body weight \[bw\]) of HCD-fed *Atp7b*^*-/-*^ rats increased compared with ND-fed *Atp7b*^*-/-*^ and *Atp7b*^*+/-*^ rats (N = 6--11). One-way analysis of variance with (*A*, *B*, *E--G*) the Tukey multiple comparisons test, or (*C*) the nonparametric Kruskal--Wallis test. N, number of analyzed animals. \*Significant to *Atp7b*^+/**-**^ ND. ^\#^Significant to *Atp7b*^+/**-**^ HCD. ^†^Significant to *Atp7b*^**-/-**^ ND. ∗^,\#,†^*P* \< .05; ∗∗^,\#\#,††^*P* \< .01; ∗∗∗^,\#\#\#,†††^*P* \< .001; ∗∗∗∗^,\#\#\#\#,††††^*P* \< .0001. TG, triglyceride.Table 1Histologic Assessment of Steatosis, Lobular Inflammation, and Hepatocyte Ballooning (NAS) in Livers of ND- and HCD-Fed *Atp7b*^*+/-*^ and *Atp7b*^*-/-*^ RatsNASGenotype+/-+/-+/-+/-+/-+/-+/-+/-+/-+/-+/-+/-+/-+/\--/\--/\--/\--/\--/\--/\--/\--/\--/\--/\--/\--/-ChowNDNDNDNDNDNDNDNDHCDHCDHCDHCDHCDHCDNDNDNDNDNDNDHCDHCDHCDHCDHCDHCDAnimal IDRat 3Rat 15Rat 1Rat 2Rat 14Rat 16Rat 17Rat 20Rat 5Rat 4Rat 6Rat 24Rat 23Rat 27Rat 31Rat 8Rat 7Rat 9Rat 29Rat 30Rat 11Rat 10Rat 12Rat 35Rat 36Rat 37Steatosis grade\<5%0000000000000005%--33%111111111\>33% to 66%22222\>66%3Lobular inflammationNo foci00\<2 foci per 200× field111111111111112--4 foci per 200× field222222222\>4 foci per 200× field33333BallooningNone00000Few balloon cells1111111111111111Many cells/ prominent ballooning22222222Diagnostic classification (NAS) Not steatohepatitis\<3221121222221 Possible/ borderline3--4343443 Definite steatohepatitis≥555665666Table 2An HCD Accelerates Disease Progression in *Atp7b*^*-/-*^ RatsAnimal IDGenotypeChowAge, *days*SexBody weight, *g*AST, *U/L*Bilirubin, *mg/dL*Rat 1+/-ND67M206181\<0.5Rat 2+/-ND73F132146\<0.5Rat 3+/-ND75F155137\<0.5Rat 4+/-HCD67F148108\<0.5Rat 5+/-HCD73F140125\<0.5Rat 6+/-HCD75F167127\<0.5Rat 7-/-ND67M214152\<0.5Rat 8-/-ND73F148181\<0.5Rat 9-/-ND75F145130\<0.5Rat 10-/-HCD67F144122\<0.5Rat 11-/-HCD73F128318[a](#tbl2fna){ref-type="table-fn"}\<0.5Rat 12-/-HCD75F144298[a](#tbl2fna){ref-type="table-fn"}\<0.5Rat 13+/-ND79M25993.5\<0.5Rat 14+/-ND79F13793.1\<0.5Rat 15+/-ND80F13995.8\<0.5Rat 16+/-ND80F16573.6\<0.5Rat 17+/-ND81M27278.5\<0.5Rat 18+/-ND81M21996.5\<0.5Rat 19+/-ND81M248222\<0.5Rat 20+/-ND82M263156\<0.5Rat 21+/-ND82M226123\<0.5Rat 22+/-HCD79M28590.4\<0.5Rat 23+/-HCD80F16865.2\<0.5Rat 24+/-HCD81M28169.9\<0.5Rat 25+/-HCD81M27277.6\<0.5Rat 26+/-HCD81M244123\<0.5Rat 27+/-HCD82M275139\<0.5Rat 28+/-HCD82M243125\<0.5Rat 29-/-ND80F16282.2\<0.5Rat 30-/-ND81M27180.5\<0.5Rat 31-/-ND82M263115\<0.5Rat 32-/-ND82M246141\<0.5Rat 33-/-ND82M26490.2\<0.5Rat 34-/-ND82M262117\<0.5Rat 35-/-HCD80F167460[a](#tbl2fna){ref-type="table-fn"}4.4[a](#tbl2fna){ref-type="table-fn"}Rat 36-/-HCD81M250486[a](#tbl2fna){ref-type="table-fn"}\<0.5Rat 37-/-HCD82M282610[a](#tbl2fna){ref-type="table-fn"}1.8[a](#tbl2fna){ref-type="table-fn"}[^3][^4]

Importantly, clinically apparent liver injury (ie, serum aspartate aminotransferase \[AST\] level, \>200 U/L) was present only in age-matched HCD-fed *Atp7b*^*-/-*^ rats, but not in ND-fed *Atp7b*^*-/-*^ or in HCD-fed *Atp7b*^*+/-*^ rats ([Figure 2](#fig2){ref-type="fig"}*A*, [Table 2](#tbl2){ref-type="table"}). Gross liver damage was further detectable by histologic analyses only in HCD-fed *Atp7b*^*-/-*^, but not in the other groups ([Figures 1](#fig1){ref-type="fig"}*D*, 2*C* and *D*, [Table 3](#tbl3){ref-type="table"}). Although in the other groups, single necrosis and apoptosis, low signs of inflammation or fibrosis, occasionally were observed, these features became severely apparent and increased significantly (vs ND-fed controls) only in HCD-fed *Atp7b*^*-/-*^ rats ([Figure 2](#fig2){ref-type="fig"}*C* and *D*, [Tables 1](#tbl1){ref-type="table"} and [3](#tbl3){ref-type="table"}). Summation of these parameters resulted in low NAS and Histologic Activity Index (HAI) scores for the other rats, but showed strongly and significantly (vs both ND-fed controls and ND-fed *Atp7b*^*-/-*^ rats) increased NAS and HAI scores for HCD-fed *Atp7b*^*-/-*^ rats ([Figures 1](#fig1){ref-type="fig"}*C* and 2*C*). Because steatosis, hepatocyte ballooning, and inflammation are the hallmarks of nonalcoholic steatohepatitis,[@bib25] such nonalcoholic steatohepatitis was present in all 6 HCD-fed *Atp7b*^*-/-*^ rats, but in only 2 of 6 HCD-fed *Atp7b*^*+/-*^ rats ([Table 1](#tbl1){ref-type="table"}).Figure 2**An HCD causes severe liver damage in *Atp7b***^***-/-***^**rats.** (*A*) Serum AST is increased specifically in HCD-fed *Atp7b*^*-/-*^ rats (N = 6--12). (*B*) After disease progression, animals are considered as having clinically apparent WD if AST level is greater than 200 U/L (*blue dashed line*). HCD causes an earlier disease onset in *Atp7b*^*-/-*^ rats compared with ND-fed animals (HCD, N = 6; ND, N = 18). (*C*) Total hepatic injury score (HAI, N = 6--8) as well as the (*D*) HAI score parameters of necrosis, apoptosis, liver cell injury, and fibrosis (N = 6--8) increase significantly only in HCD-fed *Atp7b*^*-/-*^ rats. One-way analysis of variance with the (*A*) Tukey multiple comparisons test, (*B*) nonlinear curve fitting, or (*C* and *D*) nonparametric Kruskal--Wallis test. N, number of analyzed animals. \*Significant to *Atp7b*^+/**-**^ ND. ^\#^Significant to *Atp7b*^+/**-**^ HCD. ^†^Significant to *Atp7b*^**-/-**^ ND. ∗^,\#,†^*P* \< .05; ∗∗^,\#\#,††^*P* \< .01; ∗∗∗^,\#\#\#,†††^*P* \< .001; ∗∗∗∗^,\#\#\#\#,††††^*P* \< .0001.Table 3Histologic Assessment of Hepatic Injury (HAI Score) in Livers of ND- and HCD-Fed *Atp7b*^*+/-*^ and *Atp7b*^*-/-*^ RatsHepatic injury scoreGenotype+/-+/-+/-+/-+/-+/-+/-+/-+/-+/-+/-+/-+/-+/\--/\--/\--/\--/\--/\--/\--/\--/\--/\--/\--/\--/-ChowNDNDNDNDNDNDNDNDHCDHCDHCDHCDHCDHCDNDNDNDNDNDNDHCDHCDHCDHCDHCDHCDAnimal IDRat 3Rat 15Rat 1Rat 2Rat 14Rat 16Rat 17Rat 20Rat 5Rat 4Rat 6Rat 24Rat 23Rat 27Rat 31Rat 8Rat 7Rat 9Rat 29Rat 30Rat 11Rat 10Rat 12Rat 35Rat 36Rat 37SteatosisLocationZone 300000000000000000Zone 1111111Azonal222222Panacinar3Microvesicular steatosisAbsent0000000000000000000Present111111111InflammationMicrogranulomasAbsent0Present111111111111111111111111111Large lipogranulomasAbsent000000000000000000000000000Present1Portal inflammationNone to minimal0000000000000000000More than minimal111111111Liver cell injuryAcidophil bodiesNone to rare0000000000000000Many111111111111Pigmented macrophagesNone to rare0000000000000000000000000Many111MegamitochondriaNone to rare000000000000000000000000000Many1Necrosis (periportal/ periseptal interface hepatitis)Piecemeal necrosisAbsent0000000000000000MildFocal, few portal areas1111111111Mild--moderateFocal, most portal areas222ModerateContinuous, approximately \<50% tracts/septa3SevereContinuous, approximately \>50% tracts/septa4Confluent necrosisAbsent000000000000000000000000000Focal confluent necrosis1Zone 3 necrosis-some areas2Zone 3 necrosis-most areas3Zone 3 necrosis+ occasional bridging (p-c)4Zone 3 necrosis+ multiple bridging (portal-central)5Panacinar/multiacinar necrosis6Lytic necrosis/apoptosis/focal inflammationNo foci0000≤1 foci per 100× field11111111111112--4 foci per 100× field2222222225--10 foci per 100× field3333\>10 foci per 200× field4FibrosisStageNone000000000000Perisunusoidal or periportal11111111111Mild, zone 31A1Moderate, zone 31BPortal/periportal1C1Perisinusoidal and periportal2222Bridging fibrosis3Cirrhosis4Other findingsMallory\'s hyalineNone to rare0000000000000000000Many111111111Total42315222278978265332101111111311

With respect to WD, we further tested for a difference in disease progression in HCD- vs ND-fed *Atp7b*^*-/-*^ rats. As can be seen in [Figure 2](#fig2){ref-type="fig"}*B*, HCD feeding led to a earlier disease onset by approximately 20 days in HCD- vs ND-fed *Atp7b*^*-/-*^ rats. This is a remarkable disease acceleration, because earlier we had determined a median survival of 106 days in ND-fed *Atp7b*^*-/-*^ rats.[@bib4] In addition, a noticeable steeper slope of the trend curve for liver damage was observed in HCD- vs ND-fed *Atp7b*^*-/-*^ rats ([Figure 2](#fig2){ref-type="fig"}*B*). Thus, HCD feeding causes severely aggravated liver damage that appears much earlier and progresses faster in HCD- vs ND-fed *Atp7b*^*-/-*^ rats.

An HCD Increases Serum and Mitochondrial Copper Load in *Atp7b*^*-/-*^ Rats {#sec1.2}
---------------------------------------------------------------------------

In WD livers, copper-loading of ceruloplasmin (Cp) is impaired because of *ATP7B* mutations.[@bib2] Consequently, Cp oxidase activity and copper concentrations in peripheral blood typically are reduced.[@bib26] Accordingly, ND-fed *Atp7b*^*-/-*^ rats presented almost no Cp oxidase activity and significantly decreased plasma copper levels compared with *Atp7b*^*+/-*^ controls ([Figure 3](#fig3){ref-type="fig"}*A* and *B*). Of note, HCD feeding of *Atp7b*^*+/-*^ rats resulted in significantly lower serum copper and Cp oxidase activity compared with ND-fed controls ([Figure 3](#fig3){ref-type="fig"}*A* and *B*). This is in line with observations in NAFLD patients, in whom reduced Cp oxidase activity was found to be associated strongly with hepatocyte ballooning or liver steatosis and therefore was suggested as a potential marker of liver dysfunction in fatty liver injury.[@bib27], [@bib28] In contrast to *Atp7b*^*+/-*^ control rats, HCD feeding of *Atp7b*^*-/-*^ rats still resulted in low Cp oxidase activity ([Figure 3](#fig3){ref-type="fig"}*A*), but in a significant increase of serum copper if compared with ND-fed *Atp7b*^*-/-*^ rats ([Figure 3](#fig3){ref-type="fig"}*B*). Such increased non-CP bound serum copper is a hallmark of overt liver damage in WD[@bib2] that may arise from disintegrated hepatocytes, because necrosis was largely present in the HCD-fed *Atp7b*^*-/-*^ rats ([Figure 2](#fig2){ref-type="fig"}*D*).Figure 3**An HCD increases the serum and mitochondrial copper load in *Atp7b***^***-/-***^**rats.** (*A*) Serum Cp activity is depleted in *Atp7b*^*-/-*^ rats. (*B*) Serum copper is decreased in *Atp7b*^*-/-*^ rats compared with *Atp7b*^*+/-*^ rats, but increases upon HCD in *Atp7b*^*-/-*^ rats. (*C* and *D*) Equally increased copper load in (*C*) whole-liver homogenate and (*D*) hepatic cytosol in either HCD- or ND-fed *Atp7b*^*-/-*^ rats. (*E*) Massive mitochondrial copper load in HCD-fed *Atp7b*^*-/-*^ rats. (*F*) The mitochondrial copper load significantly correlates with NAS and HAI score (N = 31). One-way analysis of variance with the (*A--E*) Tukey multiple comparisons test (N = 6--12), or (*F*) Spearman correlation. \*Significant to *Atp7b*^+/**-**^ ND. ^\#^Significant to *Atp7b*^+/**-**^ HCD. ^†^Significant to *Atp7b*^**-/-**^ ND. ∗^,\#,†^*P* \< .05; ∗∗^,\#\#,††^*P* \< .01; ∗∗∗^,\#\#\#,†††^*P* \< .001; ∗∗∗∗^,\#\#\#\#,††††^*P* \< .0001. Cu, copper.

WD *Atp7b*^*-/-*^ rats, either ND- or HCD-fed, accumulated comparable copper amounts in whole liver homogenates and liver cytosol ([Figure 3](#fig3){ref-type="fig"}*C* and *D*). This finding shows a comparable copper intake via the ND/tap water diet vs the HCD/sugar water diet, respectively. In contrast, however, an excessive increase in copper was found in mitochondria isolated from HCD- vs ND-fed *Atp7b*^*-/-*^ rats ([Figure 3](#fig3){ref-type="fig"}*E*). Of note, a significant increase in mitochondrial copper also was determined in HCD- vs ND-fed control *Atp7b*^*+/-*^ rats. Importantly, such increased mitochondrial copper significantly correlated with a higher NAS and a progressive HAI score ([Figure 3](#fig3){ref-type="fig"}*F*).

An HCD Strongly Amplifies Hepatic Mitochondrial Damage in *Atp7b*^*-/-*^ Rats {#sec1.3}
-----------------------------------------------------------------------------

Structural and functional alterations in liver mitochondria are early key features in WD patients[@bib5], [@bib8], [@bib29] and related animal models.[@bib5], [@bib30] Mitochondrial alterations also are prominent features in NAFLD patients[@bib11], [@bib12] and related animal models.[@bib13], [@bib31] We therefore hypothesized that the combined effect of genetically driven copper accumulation owing to the *Atp7b* knockout and metabolic disturbance induced by the high-calorie nutrition may accelerate the deterioration of hepatic mitochondria.

In full agreement with this supposition, feeding *Atp7b*^*-/-*^ rats with an HCD severely affected their hepatic mitochondria ([Figure 4](#fig4){ref-type="fig"}). Compared with mitochondria from ND-fed *Atp7b*^*-/-*^ rats and from control (*Atp7b*^*+/-*^) rats, mitochondria from HCD-fed *Atp7b*^*-/-*^ rats appeared with detached inner and outer membranes, prominent matrix condensations, and ballooned cristae ([Figure 4](#fig4){ref-type="fig"}*A* and *B*, arrows). Such typical WD features were partly observed in mitochondria from age-matched ND-fed *Atp7b*^*-/-*^ rats, albeit to a significantly lower extent ([Figure 4](#fig4){ref-type="fig"}*B*, and quantification in 4*C*). In contrast to mitochondria from ND-fed *Atp7b*^*+/-*^ rats, HCD-fed *Atp7b*^*+/-*^ mitochondria had partly rounded vesicular cristae that also were abundantly present in HCD-fed *Atp7b*^*-/-*^ mitochondria ([Figure 4](#fig4){ref-type="fig"}*A* and *B*, asterisks). Thus, hepatic mitochondria are affected in structure by both copper deposition and HCD, and their combination resulted in a most severe mitochondrial phenotype.Figure 4**An HCD amplifies hepatic mitochondrial damage in WD *Atp7b***^***-/-***^**rats.** (*A* and *B*) Mitochondria either (*A*) in situ (*scale bar*: 250 nm) or (*B*) isolated (*scale bar*: 1 μm) from HCD-fed *Atp7b*^*-/-*^ rats presenting with severe structural alterations, including detachments of the mitochondrial inner and outer membranes (*arrows*) or matrix condensations together with ballooned cristae (*asterisk*). (*C*) Quantification of structurally altered mitochondria from the 4 animal groups. One-way analysis of variance with the Tukey multiple comparisons test (N = 2--3, 350--750 mitochondria per group of animal). \*Significant to *Atp7b*^+/**-**^ ND. ^\#^Significant to *Atp7b*^+/**-**^ HCD. ^†^Significant to *Atp7b*^**-/-**^ ND. ∗^,\#,†^*P* \< .05; ∗∗^,\#\#,††^*P* \< .01; ∗∗∗^,\#\#\#,†††^*P* \< .001; ∗∗∗∗^,\#\#\#\#,††††^*P* \< .0001.

These structural impairments were paralleled by remarkable mitochondrial functional deficits. The capacity to produce ATP was significantly lower in mitochondria from either HCD-fed *Atp7b*^*+/-*^ or ND-fed *Atp7b*^*-/-*^ rats in comparison with those from ND-fed *Atp7b*^*+/-*^ controls ([Figure 5](#fig5){ref-type="fig"}*A*). However, the strongest decrease in ATP production capacity was determined in mitochondria from HCD-fed *Atp7b*^*-/-*^ rats, in which ATP production capacity was significantly lower than in all other tested mitochondrial populations ([Figure 5](#fig5){ref-type="fig"}*A*). In addition, the lowest, albeit not significantly decreased, mean ATP synthase (F~1~F~O~) activity was found in mitochondria from HCD-fed *Atp7b*^*-/-*^ rats ([Figure 5](#fig5){ref-type="fig"}*B*). In contrast, HCD feeding hardly affected mitochondrial oxygen consumption ([Figure 5](#fig5){ref-type="fig"}*C*) and did not change respiratory control ratios ([Figure 5](#fig5){ref-type="fig"}*D*) because only nonsignificant tendencies for increased succinate-linked, leak, and maximum oxygen consumption rates were observed in the restricted number of investigated HCD- vs ND-fed animals. It thus remains for future studies to evaluate whether these alterations do or do not contribute to mitochondrial dysfunction in HCD-fed *Atp7b*^*-/-*^ rats.Figure 5**An HCD severely impairs mitochondrial function in *Atp7b***^***-/-***^**rats.** (*A*) HCD feeding significantly reduces mitochondrial ATP production capacity in *Atp7b*^*-/-*^ rats (N = 5--7). (*B*) Tendentiously lowest F~1~F~O~ activity (ATP synthase, normalized to CS activity) in mitochondria from HCD-fed *Atp7b*^*-/-*^ rats (N = 5). HCD feeding (*C*) hardly affected mitochondrial oxygen consumption and (*D*) did not change respiratory control ratios (RCR; N = 3). (*E* and *F*) Strongly increased H~2~O~2~ emergence from mitochondria of HCD-fed *Atp7b*^*-/-*^ rats using either (*E*) succinate/rotenone and ADP or (*F*) glutamate/malate as substrates (N = 5). One-way analysis of variance with the Tukey multiple comparisons test. \*Significant to *Atp7b*^+/**-**^ ND. ^\#^Significant to *Atp7b*^+/**-**^ HCD. ^†^Significant to *Atp7b*^**-/-**^ ND. ∗^,\#,†^*P* \< .05; ∗∗^,\#\#,††^*P* \< .01; ∗∗∗^,\#\#\#,†††^*P* \< .001; ∗∗∗∗^,\#\#\#\#,††††^*P* \< .0001. CII-linked_P, succinate-linked phosphorylation; LEAK, oxygen consumption upon oligomycin treatment; ETS, electron transfer system capacity in a noncoupled carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP)-treated state.

Importantly, mitochondria from HCD-fed *Atp7b*^*-/-*^ rats appeared with 2 highly cell-toxic features that were changed significantly in comparison with the mitochondrial populations from all other rats. The first was a significantly lower ATP production ([Figure 5](#fig5){ref-type="fig"}*A*), and the second was that only mitochondria from HCD-fed *Atp7b*^*-/-*^ rats showed significantly enhanced mitochondrial H~2~O~2~ emergence, whether tested with either respiratory complex II--linked succinate ([Figure 5](#fig5){ref-type="fig"}*E*) or with respiratory complex I--linked glutamate/malate ([Figure 5](#fig5){ref-type="fig"}*F*) as substrates. Appreciable mitochondrial reactive oxygen species (ROS) were neither emerging from mitochondria from (still) healthy ND-fed WD rats nor from HCD-fed control rats, but were exclusive features of severely damaged mitochondria in HCD-fed *Atp7b*^*-/-*^ rats.

An HCD Increases Enzyme Abundancies of Hepatic Lipid and Bile Salt Synthesis in *Atp7b*^*-/-*^ Rats {#sec1.4}
---------------------------------------------------------------------------------------------------

How does the combined challenge of decreased copper excretion (owing to *Atp7b* deletion) and increased fatty acid intake (via the HCD) alter hepatic lipid metabolism? To address this question, we subjected liver homogenates of *Atp7b*^*+/-*^ and *Atp7b*^*-/-*^ rats, either ND- or HCD-fed, to a quantitative proteomic comparison ([Table 4](#tbl4){ref-type="table"}, [Table 5](#tbl5){ref-type="table"}, [Table 6](#tbl6){ref-type="table"}, [Table 7](#tbl7){ref-type="table"}). This analysis provided evidence for a strongly increased mitochondrial ß-oxidation in HCD-fed *Atp7b*^*-/-*^ rats ([Table 4](#tbl4){ref-type="table"}). This finding agrees well with our earlier results observed in wild-type mice fed an HCD for a prolonged time, and may be an adaptive response to the increased nutritive fatty acid supply.[@bib13], [@bib14] In further agreement, we also observed higher levels of lipid biosynthesis enzymes, partly in HCD-fed *Atp7b*^*+/-*^ control rats, but very prominently in HCD-fed *Atp7b*^*-/-*^ rats ([Table 5](#tbl5){ref-type="table"}). In line with these observations, increased triglyceride levels were observed in livers from HCD- vs ND-fed rats ([Figure 1](#fig1){ref-type="fig"}*B*), but not in serum ([Figure 6](#fig6){ref-type="fig"}*A*), and only mildly nonsignificantly increased levels of serum nonesterified free fatty acids ([Figure 6](#fig6){ref-type="fig"}*B*). Thus, the highly increased supply of fatty acids via the HCD vs ND[@bib14] plausibly causes a 2-fold adaptation in hepatocytes: first, their increased degradation in mitochondria via ß-oxidation, and, second, their esterification to triglycerides, which preferentially are stored in cytosol.Table 4Quantitative Proteome Comparisons of Liver Homogenate Proteins of the ^-/-^ ND, ^+/-^ HCD, and ^-/-^ HCD Groups Vs ^+/-^ ND Group: Fatty Acid Degradation (ß-Oxidation)SymbolDescription-/- ND vs +/- ND+/- HCD vs +/- ND-/- HCD vs +/- NDCellular localizationAcot13Acyl-CoA thioesterase 130.871.123.12[a](#tbl4fna){ref-type="table-fn"}MitochondrionEchdc2Enoyl-CoA hydratase domain containing 21.081.002.39[a](#tbl4fna){ref-type="table-fn"}MitochondrionEchdc3Enoyl-CoA hydratase domain containing 31.150.902.11[a](#tbl4fna){ref-type="table-fn"}MitochondrionEtfdhElectron-transferring-flavoprotein dehydrogenase1.160.842.09[a](#tbl4fna){ref-type="table-fn"}MitochondrionIvdIsovaleryl-CoA dehydrogenase1.261.333.03[a](#tbl4fna){ref-type="table-fn"}MitochondrionMceeMethylmalonyl CoA epimerase0.941.142.68[a](#tbl4fna){ref-type="table-fn"}MitochondrionAcadsbAcyl-CoA dehydrogenase, short/branched chain0.931.73[b](#tbl4fnb){ref-type="table-fn"}1.90[b](#tbl4fnb){ref-type="table-fn"}MitochondrionDecr12,4-Dienoyl CoA reductase 1, mitochondrial0.990.60[b](#tbl4fnb){ref-type="table-fn"}1.52[b](#tbl4fnb){ref-type="table-fn"}MitochondrionAcaa2Acetyl-CoA acyltransferase 20.990.931.65[b](#tbl4fnb){ref-type="table-fn"}MitochondrionAcadsAcyl-CoA dehydrogenase, C-2 to C-3 short chain0.990.951.56[b](#tbl4fnb){ref-type="table-fn"}MitochondrionAuhAdenosine-uridine RNA binding protein/enoyl-CoA hydratase1.091.031.58[b](#tbl4fnb){ref-type="table-fn"}MitochondrionEchs1Enoyl-CoA hydratase, short chain, 1, mitochondrial0.901.282.00[b](#tbl4fnb){ref-type="table-fn"}MitochondrionEtfaElectron-transfer-flavoprotein, α polypeptide0.981.131.98[b](#tbl4fnb){ref-type="table-fn"}MitochondrionEtfbElectron-transfer-flavoprotein, β polypeptide1.081.211.79[b](#tbl4fnb){ref-type="table-fn"}MitochondrionGcdhGlutaryl-CoA dehydrogenase0.861.091.91[b](#tbl4fnb){ref-type="table-fn"}MitochondrionHacl12-Hydroxyacyl-CoA lyase 11.240.751.92[b](#tbl4fnb){ref-type="table-fn"}MitochondrionHadhHydroxyacyl-CoA dehydrogenase0.960.751.81[b](#tbl4fnb){ref-type="table-fn"}MitochondrionMutMethylmalonyl CoA mutase1.091.291.67[b](#tbl4fnb){ref-type="table-fn"}MitochondrionPccaPropionyl-CoA carboxylase, α polypeptide1.081.191.81[b](#tbl4fnb){ref-type="table-fn"}MitochondrionPccbPropionyl-CoA carboxylase, β polypeptide1.001.111.96[b](#tbl4fnb){ref-type="table-fn"}MitochondrionAcot2Acyl-CoA thioesterase 21.100.40[a](#tbl4fna){ref-type="table-fn"}0.65[b](#tbl4fnb){ref-type="table-fn"}MitochondrionAcad9Acyl-CoA dehydrogenase family, member 90.760.960.63[b](#tbl4fnb){ref-type="table-fn"}MitochondrionMmaaMethylmalonic aciduria (cobalamin deficiency) cblA type1.101.330.55[b](#tbl4fnb){ref-type="table-fn"}MitochondrionEci1Enoyl-CoA delta isomerase 10.890.50[b](#tbl4fnb){ref-type="table-fn"}0.70MitochondrionEhhadhEnoyl-CoA, hydratase/3-hydroxyacyl CoA dehydrogenase1.200.65[b](#tbl4fnb){ref-type="table-fn"}0.99MitochondrionHadhaHydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), α subunit0.860.62[b](#tbl4fnb){ref-type="table-fn"}1.07MitochondrionAcad10Acyl-CoA dehydrogenase family, member 100.860.901.30MitochondrionAcad11Acyl-CoA dehydrogenase family, member 110.910.900.75MitochondrionAcad8Acyl-CoA dehydrogenase family, member 80.971.261.02MitochondrionAcadlAcyl-CoA dehydrogenase, long chain1.070.791.26MitochondrionAcadmAcyl-CoA dehydrogenase, C-4 to C-12 straight chain0.951.040.99MitochondrionAcadvlAcyl-CoA dehydrogenase, very long chain0.870.720.98MitochondrionCpt1aCarnitine palmitoyltransferase 1a, liver1.100.680.94MitochondrionCpt2Carnitine palmitoyltransferase 20.870.811.01MitochondrionMcatMalonyl-CoA-acyl carrier protein transacylase (mitochondrial)0.710.741.12MitochondrionMecrMitochondrial trans-2-enoyl-CoA reductase0.931.061.32MitochondrionAcox2Acyl-CoA oxidase 2, branched chain1.080.832.54[a](#tbl4fna){ref-type="table-fn"}Peroxisome, mitochondrionPhyhPhytanoyl-CoA 2-hydroxylase1.201.482.39[a](#tbl4fna){ref-type="table-fn"}Peroxisome, mitochondrionAbcd3ATP-binding cassette, subfamily D, member 30.950.64[b](#tbl4fnb){ref-type="table-fn"}0.77Peroxisome, mitochondrionEch1Enoyl-CoA hydratase 1, peroxisomal1.010.66[b](#tbl4fnb){ref-type="table-fn"}1.06Peroxisome, mitochondrionAcox3Acyl-CoA oxidase 3, pristanoyl1.000.751.12Peroxisome, mitochondrionEci3Enoyl-CoA delta isomerase 30.910.911.34Peroxisome, mitochondrionEci3Enoyl-CoA delta isomerase 30.770.910.85Peroxisome, mitochondrionSlc27a2Solute carrier family 27 (fatty acid transporter), member 21.030.821.07ER, mitochondrionHacl12-Hydroxyacyl-CoA lyase 11.240.751.92[b](#tbl4fnb){ref-type="table-fn"}PeroxisomeAcot4Acyl-CoA thioesterase 41.100.48[a](#tbl4fna){ref-type="table-fn"}0.44[a](#tbl4fna){ref-type="table-fn"}PeroxisomeAcot8Acyl-CoA thioesterase 81.050.910.49[a](#tbl4fna){ref-type="table-fn"}Peroxisome, cytoplasmAcox1Acyl-CoA oxidase 1, palmitoyl1.090.62[b](#tbl4fnb){ref-type="table-fn"}1.17PeroxisomeAcaa1aAcetyl-CoA acyltransferase 11.011.000.82PeroxisomeAcot12Acyl-CoA thioesterase 121.040.860.99CytoplasmAcox1Acyl-CoA oxidase 1, palmitoyl0.870.811.49PeroxisomeDecr22,4-dienoyl CoA reductase 2, peroxisomal1.080.800.84PeroxisomeHadhbHydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), β subunit0.920.710.97PeroxisomeHsd17b4Hydroxysteroid (17-β) dehydrogenase 41.040.851.01Peroxisome[^5][^6][^7][^8]Table 5Quantitative Proteome Comparisons of Liver Homogenate Proteins of the ^-/-^ ND, ^+/-^ HCD, and ^-/-^ HCD Groups Vs ^+/-^ ND Group: Fatty Acid and Triglyceride SynthesisSymbolDescription-/- ND vs +/- ND+/- HCD vs +/- ND-/- HCD vs +/- NDCellular localizationFatty acid synthesis Acsm3Acyl-CoA synthetase medium-chain family member 30.842.79[a](#tbl5fna){ref-type="table-fn"}4.25[a](#tbl5fna){ref-type="table-fn"}Mitochondrion Acss2Acyl-CoA synthetase short-chain family member 21.221.56[b](#tbl5fnb){ref-type="table-fn"}2.09[a](#tbl5fna){ref-type="table-fn"}Cytoplasm, nucleus Elovl5Elongation of very long chain fatty acids protein 51.64[b](#tbl5fnb){ref-type="table-fn"}0.892.12[a](#tbl5fna){ref-type="table-fn"}ER TecrTrans-2,3-enoyl-CoA reductase1.421.012.85[a](#tbl5fna){ref-type="table-fn"}ER Acsl1Acyl-CoA synthetase long-chain family member 11.140.833.46[a](#tbl5fna){ref-type="table-fn"}ER, mitochondrion Acsm1Acyl-CoA synthetase medium-chain family member 10.921.062.35[a](#tbl5fna){ref-type="table-fn"}Mitochondrion Acss3Acyl-CoA synthetase short-chain family member 30.901.262.39[a](#tbl5fna){ref-type="table-fn"}Mitochondrion Fads2Fatty acid desaturase 20.873.25[a](#tbl5fna){ref-type="table-fn"}1.62[b](#tbl5fnb){ref-type="table-fn"}ER Hsd17b8Hydroxysteroid (17-β) dehydrogenase 80.950.981.83[b](#tbl5fnb){ref-type="table-fn"}Mitochondrion LOC683884Similar to acyl carrier protein, mitochondrial precursor1.161.031.52[b](#tbl5fnb){ref-type="table-fn"}Mitochondrion AcacbAcetyl-CoA carboxylase β1.301.371.89[b](#tbl5fnb){ref-type="table-fn"}Mitochondrion, nucleus PecrPeroxisomal trans-2-enoyl-CoA reductase0.980.971.77[b](#tbl5fnb){ref-type="table-fn"}Peroxisome, mitochondrion Acsm1Acyl-CoA synthetase medium-chain family member 10.673.43[a](#tbl5fna){ref-type="table-fn"}0.18[a](#tbl5fna){ref-type="table-fn"}Mitochondrion Acsf2Acyl-CoA synthetase family member 20.681.66[b](#tbl5fnb){ref-type="table-fn"}0.56[b](#tbl5fnb){ref-type="table-fn"}Mitochondrion Acsm5Acyl-CoA synthetase medium-chain family member 50.59[b](#tbl5fnb){ref-type="table-fn"}0.56[b](#tbl5fnb){ref-type="table-fn"}0.53[b](#tbl5fnb){ref-type="table-fn"}Mitochondrion FasnFatty acid synthase1.080.26[a](#tbl5fna){ref-type="table-fn"}0.77Cytoplasm AclyATP citrate lyase1.060.34[a](#tbl5fna){ref-type="table-fn"}0.97Nucleus AcacaAcetyl-CoA carboxylase α1.180.55[b](#tbl5fnb){ref-type="table-fn"}0.83Mitochondrion Acsl4Acyl-CoA synthetase long-chain family member 41.170.65[b](#tbl5fnb){ref-type="table-fn"}1.29Mitochondrion Hacd23-hydroxyacyl-CoA dehydratase 21.001.311.45ER Hsd17b12Hydroxysteroid (17-β) dehydrogenase 121.030.881.11ER Hacd33-hydroxyacyl-CoA dehydratase 31.321.161.10ER, mitochondrion Ppt1Palmitoyl-protein thioesterase 11.051.060.81Lysosome Acsf3Acyl-CoA synthetase family member 30.931.221.03Mitochondrion Acsl5Acyl-CoA synthetase long-chain family member 51.270.681.16Mitochondrion Cbr4Carbonyl reductase 40.890.831.04Mitochondrion McatMalonyl-CoA-acyl carrier protein transacylase0.710.741.12Mitochondrion MecrMitochondrial trans-2-enoyl-CoA reductase0.931.061.32Mitochondrion Slc25a1Solute carrier family 25 (mitochondrial carrier, citrate transporter), member 11.201.031.30MitochondrionTriglyceride synthesis GkGlycerol kinase1.300.752.16[a](#tbl5fna){ref-type="table-fn"}Mitochondrion GpamGlycerol-3-phosphate acyltransferase1.160.941.97[b](#tbl5fnb){ref-type="table-fn"}Mitochondrion AgmoAlkylglycerol monooxygenase0.820.690.75ER Dgat1Diacylglycerol O-acyltransferase 11.091.131.24ER[^9][^10][^11][^12]Table 6Quantitative Proteome Comparisons of Liver Homogenate Proteins of the ^-/-^ ND, ^+/-^ HCD, and ^-/-^ HCD Groups Vs ^+/-^ ND Group: Ketone Body and Cholesterol SynthesisSymbolDescription-/- ND vs +/- ND+/- HCD vs +/- ND-/- HCD vs +/- NDCellular localizationKetone body synthesis Acss3Acyl-CoA synthetase short-chain family member 30.901.262.39[a](#tbl6fna){ref-type="table-fn"}Mitochondrion Bdh13-Hydroxybutyrate dehydrogenase, type 10.950.823.20[a](#tbl6fna){ref-type="table-fn"}Mitochondrion Hmgcs23-Hydroxy-3-methylglutaryl-CoA synthase 21.040.58[b](#tbl6fnb){ref-type="table-fn"}1.95[b](#tbl6fnb){ref-type="table-fn"}Mitochondrion Acat1Acetyl-CoA acetyltransferase 10.920.821.30Mitochondrion Hmgcl3-Hydroxymethyl-3-methylglutaryl-CoA lyase0.810.871.43MitochondrionCholesterol synthesis Acat2Acetyl-CoA acetyltransferase 21.73[b](#tbl6fnb){ref-type="table-fn"}2.67[a](#tbl6fna){ref-type="table-fn"}8.79[a](#tbl6fna){ref-type="table-fn"}Nucleus Hsd17b7Hydroxysteroid (17-β) dehydrogenase 71.57[b](#tbl6fnb){ref-type="table-fn"}2.03[a](#tbl6fna){ref-type="table-fn"}6.52[a](#tbl6fna){ref-type="table-fn"}Cell membrane Idi1Isopentenyl-diphosphate delta isomerase 11.63[b](#tbl6fnb){ref-type="table-fn"}4.08[a](#tbl6fna){ref-type="table-fn"}3.39[a](#tbl6fna){ref-type="table-fn"}Peroxisome Msmo1Methylsterol monooxygenase 11.70[b](#tbl6fnb){ref-type="table-fn"}3.25[a](#tbl6fna){ref-type="table-fn"}4.16[a](#tbl6fna){ref-type="table-fn"}ER Cyp51Cytochrome P450, family 51, lanosterol 14-α demethylase1.312.60[a](#tbl6fna){ref-type="table-fn"}4.75[a](#tbl6fna){ref-type="table-fn"}Unknown Hmgcs13-Hydroxy-3-methylglutaryl-CoA synthase 1 (soluble)1.082.60[a](#tbl6fna){ref-type="table-fn"}3.74[a](#tbl6fna){ref-type="table-fn"}Cytoplasm MvkMevalonate kinase1.212.21[a](#tbl6fna){ref-type="table-fn"}4.12[a](#tbl6fna){ref-type="table-fn"}Peroxisome SqleSqualene epoxidase1.473.62[a](#tbl6fna){ref-type="table-fn"}4.05[a](#tbl6fna){ref-type="table-fn"}ER EbpEmopamil binding protein (sterol isomerase)1.66[b](#tbl6fnb){ref-type="table-fn"}1.68[b](#tbl6fnb){ref-type="table-fn"}2.71[a](#tbl6fna){ref-type="table-fn"}ER Dhcr77-Dehydrocholesterol reductase1.371.77[b](#tbl6fnb){ref-type="table-fn"}2.42[a](#tbl6fna){ref-type="table-fn"}ER LssLanosterol synthase (2,3-oxidosqualene-lanosterol cyclase)1.401.98[b](#tbl6fnb){ref-type="table-fn"}4.01[a](#tbl6fna){ref-type="table-fn"}ER PmvkPhosphomevalonate kinase1.221.73[b](#tbl6fnb){ref-type="table-fn"}4.47[a](#tbl6fna){ref-type="table-fn"}Peroxisome Tm7sf2Transmembrane 7 superfamily member 21.171.88[b](#tbl6fnb){ref-type="table-fn"}3.84[a](#tbl6fna){ref-type="table-fn"}ER FdpsFarnesyl diphosphate synthase1.491.303.99[a](#tbl6fna){ref-type="table-fn"}Cytoplasm MvdMevalonate (diphospho) decarboxylase1.012.00[a](#tbl6fna){ref-type="table-fn"}1.94[b](#tbl6fnb){ref-type="table-fn"}Peroxisome Fdft1Farnesyl diphosphate farnesyl transferase 11.221.99[b](#tbl6fnb){ref-type="table-fn"}1.80[b](#tbl6fnb){ref-type="table-fn"}ER Hmgcs23-Hydroxy-3-methylglutaryl-CoA synthase 21.040.58[b](#tbl6fnb){ref-type="table-fn"}1.95[b](#tbl6fnb){ref-type="table-fn"}Mitochondrion Acaa2Acetyl-CoA acyltransferase 20.990.931.65[b](#tbl6fnb){ref-type="table-fn"}Mitochondrion Dhcr2424-Dehydrocholesterol reductase1.171.87[b](#tbl6fnb){ref-type="table-fn"}1.35ER, Golgi Acat1Acetyl-CoA acetyltransferase 10.920.821.30Mitochondrion Hmgcl3-Hydroxymethyl-3-methylglutaryl-CoA lyase0.810.871.43Mitochondrion NsdhlNAD(P)-dependent steroid dehydrogenase-like1.060.921.00ER[^13][^14][^15][^16]Table 7Quantitative Proteome Comparisons of Liver Homogenate Proteins of the ^-/-^ ND, ^+/-^ HCD, and ^-/-^ HCD Groups Vs ^+/-^ ND Group: Bile Acid Synthesis and TransportSymbolDescription-/- ND vs +/- ND+/- HCD vs +/- ND-/- HCD vs +/- NDCellular localizationBile synthesis Acox2Acyl-CoA oxidase 2, branched chain1.080.832.54[a](#tbl7fna){ref-type="table-fn"}Mitochondrion, peroxisome Amacrα-Methylacyl-CoA racemase1.070.992.34[a](#tbl7fna){ref-type="table-fn"}Mitochondrion, peroxisome Cyp8b1Cytochrome P450, family 8, subfamily b, polypeptide 10.970.992.09[a](#tbl7fna){ref-type="table-fn"}ER Acot8Acyl-CoA thioesterase 81.050.910.49[a](#tbl7fna){ref-type="table-fn"}Mitochondrion, peroxisomeBile transport and secretion Abcc2ATP-binding cassette, subfamily C, member 20.971.343.51[a](#tbl7fna){ref-type="table-fn"}Membrane Slc10a1Solute carrier family 10 (sodium/bile acid cotransporter), member 11.69[b](#tbl7fnb){ref-type="table-fn"}1.283.49[a](#tbl7fna){ref-type="table-fn"}Cell membrane Slc22a7Solute carrier family 22 (organic anion transporter), member 71.170.983.85[a](#tbl7fna){ref-type="table-fn"}Cell membrane Slc22a1Solute carrier family 22 (organic cation transporter), member 11.160.952.25[a](#tbl7fna){ref-type="table-fn"}Cell membrane Slc27a5Solute carrier family 27 (fatty acid transporter), member 51.360.984.37[a](#tbl7fna){ref-type="table-fn"}ER Slco1a1Solute carrier organic anion transporter family, member 1a10.940.866.44[a](#tbl7fna){ref-type="table-fn"}Cell membrane Slco1a4Solute carrier organic anion transporter family, member 1a41.302.45[a](#tbl7fna){ref-type="table-fn"}10.96[a](#tbl7fna){ref-type="table-fn"}Cell membrane Slco1b2Solute carrier organic anion transporter family, member 1B21.350.882.41[a](#tbl7fna){ref-type="table-fn"}Cell membrane Stard10Steroidogenic acute regulatory protein-related lipid transfer domain containing 101.381.142.58[a](#tbl7fna){ref-type="table-fn"}Cell membrane Sult2a1Sulfotransferase family 2A, dehydroepiandrosterone--preferring, member 11.53[b](#tbl7fnb){ref-type="table-fn"}1.066.69[a](#tbl7fna){ref-type="table-fn"}Cytoplasm Sult2a1Sulfotransferase family 2A, dehydroepiandrosterone--preferring, member 12.09[a](#tbl7fna){ref-type="table-fn"}1.004.40[a](#tbl7fna){ref-type="table-fn"}Cytoplasm Abcb1aATP-binding cassette, subfamily B, member 1A0.55[b](#tbl7fnb){ref-type="table-fn"}1.340.34[a](#tbl7fna){ref-type="table-fn"}Cell membrane Abcc3ATP-binding cassette, subfamily C, member 30.65[b](#tbl7fnb){ref-type="table-fn"}0.57[b](#tbl7fnb){ref-type="table-fn"}0.08[a](#tbl7fna){ref-type="table-fn"}Cell membrane Ephx1Epoxide hydrolase 1, microsomal (xenobiotic)0.771.230.35[a](#tbl7fna){ref-type="table-fn"}ER LdlrLow-density lipoprotein receptor0.990.65[b](#tbl7fnb){ref-type="table-fn"}0.49[a](#tbl7fna){ref-type="table-fn"}Cell membrane, Golgi Abcb11ATP-binding cassette, subfamily B, member 111.001.141.06Cell membrane[^17][^18][^19][^20]Figure 6**An HCD increases total serum bile salts in *Atp7b***^***-/-***^**rats.** (*A*) Serum triglycerides, (*B*) serum nonesterified fatty acids (NEFAs), and (*C*) total serum cholesterol do not differ between ND and HCD groups (N = 4--5). (*D*) Total serum bile salts increase in HCD-fed *Atp7b*^*-/-*^ rats (N = 3--5). One-way analysis of variance with the Tukey multiple comparisons test. \*Significant to *Atp7b*^+/**-**^ ND. ^\#^Significant to *Atp7b*^+/**-**^ HCD. ^†^Significant to *Atp7b*^**-/-**^ ND. ∗^,\#,†^*P* \< .05; ∗∗^,\#\#,††^*P* \< .01; ∗∗∗^,\#\#\#,†††^*P* \< .001; ∗∗∗∗^,\#\#\#\#,††††^*P* \< .0001.

How would hepatocytes deal with an increasing acetyl coenzyme A (acetyl-CoA) amount resulting from increased mitochondrial ß-oxidation of fatty acids? One response is increased lipid biosynthesis and storage. However, acetyl-CoA also is the precursor in hepatic ketogenesis and cholesterol biosynthesis.[@bib32] The proteomic comparison showed only slightly increased to doubled levels of the ketogenic mitochondrial enzymes ([Table 6](#tbl6){ref-type="table"}), and first analyses of serum levels indicated comparable 3-hydroxybutyrate levels in HCD- vs ND-fed *Atp7b*^*-/-*^ rats (3.25 ± 0.07 vs 3.58 ± 1.23 mg/dL, respectively), indicating minor effects on ketogenesis. In contrast, approximately 4-fold increased enzyme levels (in comparison with ND-fed control rats) were found for nearly the whole cholesterol biosynthesis pathway ([Table 6](#tbl6){ref-type="table"}). Moreover, in HCD-fed *Atp7b*^*-/-*^ rats, strong increases were found in enzymes responsible for cholesterol excretion via bile acid biosynthesis and bile excretion ([Table 7](#tbl7){ref-type="table"}). These data indicated an increased synthesis of cholesterol and plausibly, consequently elevated bile salts in HCD-fed *Atp7b*^*-/-*^ rats. In fact, although unchanged cholesterol levels were determined in serum ([Figure 6](#fig6){ref-type="fig"}*C*) of HCD- vs ND-fed rats, significantly increased bile salt levels were determined only in HCD-fed *Atp7b*^*-/-*^ rat serum ([Figure 6](#fig6){ref-type="fig"}*D*).

The High-Affinity Copper Binding Peptide MB Efficiently Reverses HCD-Induced Mitochondrial Dysfunction and Improves Liver Integrity in *Atp7b*^*-/-*^ Rats {#sec1.5}
----------------------------------------------------------------------------------------------------------------------------------------------------------

The bacteria-derived peptide MB prevents disease progression in *Atp7b*^*-/-*^ rats.[@bib4], [@bib5] This therapeutic effect is largely owing to efficient hepatic de-coppering ([Figure 7](#fig7){ref-type="fig"}*A*), most prominently in the mitochondrial compartment restoring their structure and function.[@bib4], [@bib5] Because we aimed here to improve the mitochondrial status in HCD-fed *Atp7b*^*-/-*^ rats as fast as possible, together with a low stress level due to therapy, we chose a once-daily treatment for 5 consecutive days only. We previously observed that such short-term treatments already resulted in mitochondrial improvement, whereas more intense treatments were needed to rescue diseased animals.[@bib5] Consequently, we assessed here whether the beneficial effect of MB treatment still would hold in HCD-fed *Atp7b*^*-/-*^ rats. Animals were treated once daily for 5 consecutive days with MB, starting at day 75 (ie, at an age when HCD-fed *Atp7b*^*-/-*^ rats presented with marked liver damage) ([Figure 2](#fig2){ref-type="fig"}*A* and *B*).Figure 7**MB rescues HCD-induced mitochondrial dysfunction in *Atp7b***^***-/-***^**rats.** (*A*) Laser ablation ICP-MS distribution maps (*lower panels*) show lower copper concentrations in liver samples from ND-fed, MB-treated *Atp7b*^*-/-*^ rats compared with untreated ND-fed *Atp7b*^*-/-*^ controls (copper concentration range, 0--500 μg/g; laser spot size, 25 μm; scan speed, 50 μm/s). (*B*) Electron micrographs of mitochondria either in situ (*upper panel*, *scale bar*: 500 nm) or isolated (*lower panel*, *scale bar*: 500 nm) show mitochondrial structure normalization upon MB treatment (*right panels*) vs untreated (*left panels*). (*C*) Quantification of isolated mitochondria with altered structure (N = 3, 700--750 mitochondria in each animal group). (*D--F*) Methanobactin treatment (*D*) decreases mitochondrial copper load (N = 5--6), (*E*) increases mitochondrial ATP production (N = 5), and (*F*) decreases mitochondrial H~2~O~2~ emergence (substrates, glutamate/malate; N = 5). Unpaired *t* test, significant if ∗∗*P* \< .01; ∗∗∗∗*P* \< .0001.

MB treatment clearly improved the mitochondrial structure, as evidenced either in situ or at the level of isolated mitochondria ([Figure 7](#fig7){ref-type="fig"}*B*). A significantly lower number of isolated mitochondria from MB-treated HCD-fed *Atp7b*^*-/-*^ rats presented with cristae detachments and matrix condensations in comparison with mitochondria from untreated HCD-fed *Atp7b*^*-/-*^ rats ([Figure 7](#fig7){ref-type="fig"}*B*, and quantification shown in [7](#fig7){ref-type="fig"}*C*). This structural normalization was paralleled by a 50% reduction in mitochondrial copper load ([Figure 7](#fig7){ref-type="fig"}*D*, [Table 8](#tbl8){ref-type="table"}), highly comparable with our previous results for this treatment regimen (ie, 32%--62% mitochondrial copper depletion using 5 single consecutive MB injections).[@bib5] Moreover, strongly enforced mitochondrial ATP production capacity ([Figure 7](#fig7){ref-type="fig"}*E*) and significantly decreased mitochondrial H~2~O~2~ emergence was observed ([Figure 7](#fig7){ref-type="fig"}*F*). Thus, a 5-day-only MB treatment efficiently ameliorated copper-induced structural and functional deficits in liver mitochondria from HCD-fed *Atp7b*^*-/-*^ rats.Table 8MB Treatment (Intraperitoneally, Once Daily for 5 Days) Reduces Liver Damage and Copper Overload in Serum, Kidney, and Livers of Female HCD-Fed *Atp7b*^*-/-*^ RatsAnimal IDRat 38Rat 39Rat 40Rat 41Rat 42-/- HCD + MB, mean-/- HCD, meanSexFemaleFemaleFemaleFemaleFemaleAge, *day*797980808080[a](#tbl8fna){ref-type="table-fn"}74[a](#tbl8fna){ref-type="table-fn"}AST, *U/L* Before227330419368545378300 After172123196136136191ndBilirubin, *mg/dL* Before\<0.5\<0.5\<0.5\<0.51.2\<0.5[a](#tbl8fna){ref-type="table-fn"}\<0.5[a](#tbl8fna){ref-type="table-fn"} After\<0.5\<0.5\<0.5\<0.5\<0.5\<0.5[a](#tbl8fna){ref-type="table-fn"}ndBody weight, *g* Before121141128122102123146 After126149134132113131ndSpleen weight, *g*0.230.150.250.230.280.230.28Visceral fat, *g*1.932.392.661.992.042.202.53Serum Cu, *ng/mL*n.d.455296224525375640Kidney Cu, *μg/g* wet weight364062441005699Liver homogenate Cu, *μg/g* wet weight318237247296284276392Mitochondrial Cu, ng/mg protein538384386445467444893[b](#tbl8fnb){ref-type="table-fn"}Mitochondrial Cu depletion, *%*[b](#tbl8fnb){ref-type="table-fn"}39.857.056.750.147.7500NAS454555a6[a](#tbl8fna){ref-type="table-fn"}HAI8108121210[a](#tbl8fna){ref-type="table-fn"}11[a](#tbl8fna){ref-type="table-fn"}[^21][^22][^23][^24]

Besides the mitochondrial status, we next investigated effects on overt liver damage upon treatment. All animals experienced a significant decrease in AST serum levels after the MB treatment vs pretreatment levels ([Figure 8](#fig8){ref-type="fig"}*A*, [Table 8](#tbl8){ref-type="table"}). One animal that additionally showed increased serum bilirubin levels before treatment returned to levels below the detection limit, and all animals regained weight, showing a positive therapeutic effect ([Table 8](#tbl8){ref-type="table"}). In addition, if compared with untreated HCD-fed *Atp7b*^*-/-*^ rats, we found significantly lower serum copper levels and a massive decrease in total serum bile salts ([Figure 8](#fig8){ref-type="fig"}*B* and *C*). Thus, overt liver damage was rescued by this short-term MB treatment. At a histologic level, however, liver damage of HCD-fed *Atp7b*^*-/-*^ rats only partially was resolved ([Figures 8](#fig8){ref-type="fig"}*D--F*), resulting in a mild but significant decrease in NAS ([Figures 8](#fig8){ref-type="fig"}*F*), while liver triglyceride levels were unchanged ([Figure 8](#fig8){ref-type="fig"}*G*).Figure 8**MB rescues overt/acute liver damage in HCD-fed *Atp7b***^***-/-***^**rats.** (*A--C*) Short-term MB treatment (*A*) significantly reduces the liver damage marker AST (comparison of HCD-fed *Atp7b*^*-/-*^ rats before and after MB treatment), and (*B* and *C*) significantly decreases serum copper and bile salts (comparison of HCD-fed *Atp7b*^*-/-*^ rats with vs without MB treatment). (*D*) Liver sections (*scale bar*: 100 μm) from MB-treated (*right panel*) vs untreated HCD-fed *Atp7b*^*-/-*^ rats (*left panel*) showed no significant reduction of lobular inflammation (*black arrow*), apoptosis (*open arrowhead*), necrosis (*black arrowhead*), fibrosis (*black asterisk*), or steatosis (*open asterisk*), as also evidenced by only slightly lower (*E*) HAI score and (*F*) NAS. (*G*) Liver triglyceride content was unchanged after MB treatment. (*A--C*, and *G*) Unpaired *t* test (N = 3--6), significant if \**P* \< .05, means ± SD; (*E* and *F*) nonparametric Mann--Whitney test (N = 5--6), significant if \**P* \< .05, medians ± range.

Discussion {#sec2}
==========

In WD, ATP7B malfunction impairs hepatic copper excretion. This leads to a progressive copper burden in mitochondria.[@bib4], [@bib5], [@bib8], [@bib30] Copper ultimately causes mitochondrial destruction, hepatocyte death, liver failure, and decease of WD *Atp7b*^*-/-*^ rats.[@bib5] We previously reported that efficient depletion of mitochondrial copper load with the high-affinity copper chelator MB leads to full recovery from even severe states of liver damage.[@bib5] Upon pausing still, the rate of mitochondrial copper re-accumulation determines the rate of re-occurring liver damage.[@bib5]

These findings show that hepatic mitochondria are exceptionally susceptible to liver copper overload, thereby being a key organelle in WD pathogenesis. However, mitochondria also readily respond to environmental changes other than increased copper by metabolic adaptations and can balance imposed challenges to different extents for a long time.[@bib13], [@bib33] We reasoned that this mitochondrial flexibility might contribute to the high variability of the clinical presentation of WD.[@bib1] The *ATP7B* genotype is not clearly predictive for the age of onset, the disease presentation or progression, or for the response to treatment.[@bib1], [@bib34] This absence of a genotype--phenotype correlation may be best exemplified by studies on genetically identical WD twins, whose clinical appearance ranged from presymptomatic phenotypes to liver failure.[@bib17], [@bib35] Consequently, it has been suggested that the WD phenotype may be highly attributable to environmental factors.[@bib35], [@bib36]

Steatosis is a frequently observed early characteristic in livers of WD patients,[@bib8], [@bib9] and mutations in the ε3 and ε4 isoforms of the apolipoprotein E gene are associated with WD onset.[@bib37], [@bib38] Moreover, mutations in the lipase gene *PNALP3* are linked to the percentage of liver steatosis in patients with WD.[@bib9] Furthermore, lower serum cholesterol levels were observed in WD patients with hepatic symptoms,[@bib39], [@bib40] and WD animal models, such as *Atp7b*^*-/-*^ mice, present a down-regulation of enzymes involved in cholesterol and lipid metabolism,[@bib22], [@bib41] whereas Long-Evans Cinnamon rats show lower serum but higher liver cholesterol and triglyceride levels.[@bib21] These studies clearly indicate a link between the lipid/cholesterol metabolism and WD pathophysiology. We therefore asked whether a steatosis-promoting diet would influence WD-related liver damage, and especially mitochondrial damage, in *Atp7b*^*-/-*^ rats. The rationale was that both enriched copper and fatty acids cause bioenergetic defects and therefore synergistically and detrimentally may coincide on hepatic mitochondria.

An HCD caused strongly increased and accelerated liver damage, evidenced by serum markers of liver damage ([Figure 2](#fig2){ref-type="fig"}*A* and *B*) and histologic assessment (HAI score and NAS). In HCD- vs ND-fed *Atp7b*^*-/-*^ rats, a drastically increased copper load was found in mitochondria, but equal cytosolic or overall hepatic copper contents. Compared with mitochondria from either HCD- or ND-fed control rats or from ND-fed *Atp7b*^*-/-*^ rats, mitochondria from HCD-fed *Atp7b*^*-/-*^ rats appeared to have the most severe mitochondrial structural alterations, a significantly lower ATP production, and a significantly enhanced mitochondrial ROS emergence. Hence, the combination of an HCD with an increasing copper load caused severe structural and functional mitochondrial impairments, whereas mitochondrial copper overload strongly correlated with progressive liver damage ([Figure 2](#fig2){ref-type="fig"}, [Figure 3](#fig3){ref-type="fig"}, [Figure 4](#fig4){ref-type="fig"}, [Figure 5](#fig5){ref-type="fig"}).

Thus, a simple change in nutrition from a normal diet to an HCD severely aggravated and accelerated WD pathophysiology in HCD-fed *Atp7b*^*-/-*^ rats. This could be the result of 2 not mutually exclusive reasons: enhanced copper uptake and/or an additional metabolic burden imposed on the hepatocytes and their mitochondria because the later organelles are both the prime site for cellular copper utilization (via complex IV of the respiratory chain) and for fatty acid degradation. Based on reports that ND-fed control animals consumed similar amounts of food and water as their HCD-fed counterparts,[@bib24] we adjusted for an equal copper supply by the 2 diets (see the [Materials and Methods](#sec3){ref-type="sec"} section). In subsequent testing, however, we found that the rats consumed less HCD than ND food, but more fructose water instead of water, respectively. Upon recalculating the supplied copper amounts, we found that the HCD/syrup diet provided approximately 18% more copper. Interestingly, this slightly increased copper supply, however, did not result in correspondingly increased liver copper levels ([Figure 3](#fig3){ref-type="fig"}) because we observed equal copper loads in total liver homogenates and in liver cytosol. To the contrary, mitochondria from HCD- vs ND-fed control animals had drastically and significantly increased copper levels ([Figure 3](#fig3){ref-type="fig"}). This may indicate that the distribution of hepatocyte copper changes upon HCD feeding. In the HCD-fed *Atp7b*^*-/-*^ rat liver mitochondria this copper overload caused severe structural and functional mitochondrial deficits ([Figures 4](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"}), paralleled by cell death ([Figure 2](#fig2){ref-type="fig"}). We recently reported that progressive mitochondrial copper accumulation causes a steady reduction of their capacity to produce ATP.[@bib5] This is owing to the direct impact of copper on the protein complexes involved in ATP production, but also ATP delivery to the cytosol.[@bib4] This bioenergetic deficit matches the clinical presentation of liver damage in *Atp7b*^*-/-*^ rats. A decrease in the ATP production capacity to 70% in comparison with mitochondria from *Atp7b*^*+/-*^ control rats was found to be critical for the onset of clinically apparent liver damage (ie, AST levels \> 200 U/L).[@bib5] In the present study, a mitochondrial ATP production capacity of 80% was preserved in young ND-fed *Atp7b*^*-/-*^ rats ([Figure 5](#fig5){ref-type="fig"}*A*). In agreement with our earlier study, these rats still were healthy ([Figure 2](#fig2){ref-type="fig"}). In a mouse study, we reported that the increased supply of fatty acids via an HCD causes lipidomic alterations in the membranes of liver mitochondria that also reduce their ATP production capacity,[@bib13] along with only mild signs of liver impairment.[@bib13] In agreement with this study, we determined a reduced mitochondrial ATP production capacity but comparatively mild signs of apparent liver damage in HCD-fed *Atp7b*^*+/-*^ control vs *Atp7b*^*-/-*^ rats (steatohepatitis was present in only 2 of 6 HCD-fed *Atp7b*^*+/-*^ rats) ([Figures 1](#fig1){ref-type="fig"}*C*, 2, and 5*A*, [Tables 1](#tbl1){ref-type="table"} and [3](#tbl3){ref-type="table"}). This situation changed when an increasing copper load coincided with steatosis: a decreased ATP production capacity to less than 40% was paralleled by severe structural impairments and strongly increased ROS emergence in mitochondria from HCD-fed *Atp7b*^*-/-*^ rats, in comparison with mitochondria from all other rats, whether HCD- or ND-fed controls or ND-fed *Atp7b*^*-/-*^ rats ([Figures 4](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"}). One interesting question for future experiments is why mitochondrial turnover and renewal via mitophagy was incapable to rescue the detrimental effects of copper and steatosis coinciding on mitochondria. Either such pathways were efficiently inactivated (possibly involving activated mechanistic target of rapamycin (mTOR) pathways), blocked by copper excess, negatively affected by bioenergetic deficits that were too strong, or simply overwhelmed. As a result, however, such mitochondrial damage strongly challenges hepatocytes, and cell death (both necrosis and apoptosis) was extensive ([Figure 2](#fig2){ref-type="fig"}*D*), paralleled by severe liver damage in HCD-fed *Atp7b*^*-/-*^ rats ([Figure 2](#fig2){ref-type="fig"}, [Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"}, [Table 3](#tbl3){ref-type="table"}). We therefore conclude that WD pathophysiology in HCD-fed *Atp7b*^*-/-*^ rats is aggravated because of a highly detrimental combination of massive copper- and fatty acid--induced impacts on liver mitochondria.

Further support for the decisive role of mitochondrial damage in the pathophysiology of HCD-fed *Atp7b*^*-/-*^ rats comes from the results of the applied short-term treatment with the copper chelator MB ([Figures 7](#fig7){ref-type="fig"} and [8](#fig8){ref-type="fig"}). We chose this drug, and applied it once daily for 5 consecutive days, to test for a fast mitochondrial recovery in HCD-fed *Atp7b*^*-/-*^ rats, as a potential remedy against acute and overt liver damage. In comparison with our earlier reports, such treatments are relatively mild because we also had applied MB 2 or 3 times daily or for increased time periods of up to 1 month.[@bib4], [@bib5] Nevertheless, this short-term MB treatment significantly reduced mitochondrial structural damage and improved mitochondrial ATP production with a concomitant decrease in ROS emergence ([Figure 7](#fig7){ref-type="fig"}). This mitochondrial amelioration was paralleled by a rescue of overt/acute liver damage in all treated animals, as serum AST levels decreased, bilirubin levels were below detection and animals regained body weight ([Table 8](#tbl8){ref-type="table"}). In addition, compared with untreated HCD-fed *Atp7b*^*-/-*^ rats, serum copper and bile salt levels, plausibly increased upon hepatocyte disintegration, significantly decreased in MB-treated HCD-fed *Atp7b*^*-/-*^ rats ([Figure 8](#fig8){ref-type="fig"}*B* and *C*).

Despite this highly beneficial effect of the applied short-term MB-treatment, mitochondrial and liver rescue was not complete. Although the mitochondrial copper content decreased to 50% ([Figure 7](#fig7){ref-type="fig"}*D*), in absolute terms, the remaining copper load still was a borderline burden ([Table 8](#tbl8){ref-type="table"}) and comparable with the values of ND-fed *Atp7b*^*-/-*^ rats ([Figure 3](#fig3){ref-type="fig"}*E*) that were about to develop hepatitis within days ([Figure 2](#fig2){ref-type="fig"}*B*). This borderline status may explain the noticeable but limited improvements in liver histology ([Figure 8](#fig8){ref-type="fig"}), and it remains for future studies to test whether prolonged/intensified MB treatments would result in a more complete reversal of mitochondrial and liver damage in HCD-fed *Atp7b*^*-/-*^ rats.

HCD feeding caused steatosis in all HCD-fed animals. In contrast, steatohepatitis was present in only 2 of 6 HCD-fed *Atp7b*^*+/-*^ rats, but in all 6 HCD-fed *Atp7b*^*-/-*^ rats ([Figure 1](#fig1){ref-type="fig"}, [Table 1](#tbl1){ref-type="table"}). Accordingly, tendentious lower levels of visceral fat ([Figure 1](#fig1){ref-type="fig"}*A*) and lower levels of liver triglycerides ([Figure 1](#fig1){ref-type="fig"}*B*) were found in HCD-fed *Atp7b*^*-/-*^ vs *Atp7b*^*+/-*^ rats, indicating a comparatively higher energy turnover in *Atp7b*^*-/-*^ livers. Indeed, mitochondrial enzymes involved in fatty acid degradation were enriched in livers of HCD-fed *Atp7b*^*+/-*^ rats, but especially in HCD-fed *Atp7b*^*-/-*^ rat livers ([Table 4](#tbl4){ref-type="table"}). Interestingly, we also observed higher abundancies of lipid biosynthesis enzymes, partly in HCD-fed *Atp7b*^*+/-*^ control rats, but very prominently in HCD-fed *Atp7b*^*-/-*^ rats ([Table 5](#tbl5){ref-type="table"}). Although these increased enzyme abundancies do not necessarily mean an enhanced flux via these pathways, the highly increased supply of fatty acids via the HCD vs ND[@bib14] indicates a 2-fold adaptation in hepatocytes: first, their increased degradation in mitochondria via ß-oxidation, and, second, their esterification to triglycerides that are preferentially stored in cytosol. Future measurements have to validate such enhanced metabolic fluxes and/or specific metabolites from these pathways. Furthermore, besides the mere levels of enzyme abundancies, metabolic enzyme activities may be modulated further via post-translational modifications such as acetylation and succinylation,[@bib42] which were not assessed in this study. Indeed, increased acetyl-CoA levels from augmented ß-oxidation may result in increased acetylation[@bib43] of mitochondrial enzymes involved in the tricarboxylic acid cycle, fatty acid oxidation, amino acid and carbohydrate metabolism, ketone body synthesis, and the urea cycle.[@bib42], [@bib44] Moreover, an increasing acetyl-CoA amount would influence not only these pathways, but also possibly would cause increased cholesterol levels because acetyl-CoA is the precursor in hepatic cholesterol biosynthesis.[@bib32] Such hepatic cholesterol accumulation has been reported in NAFLD patients and rodents[@bib45] and correlated with histologic severity of the disease and thus seems to be associated with HCD malnutrition. In fact, increased enzyme abundancies for nearly the whole cholesterol biosynthesis pathway were found in HCD-fed *Atp7b*^*-/-*^ rat livers ([Table 6](#tbl6){ref-type="table"}). Unexpectedly, however, we did not observe specifically increased cholesterol levels in these animals ([Figure 6](#fig6){ref-type="fig"}*C*). This may have been prevented by an increased routing of cholesterol into bile salts because we determined 2- to 11-fold increases in abundancies of enzymes involved in bile salt synthesis and bile excretion in HCD-fed *Atp7b*^*-/-*^ rat livers ([Table 7](#tbl7){ref-type="table"}). In agreement, we found increased serum bile salts only in serum of HCD-fed *Atp7b*^*-/-*^ rats ([Figure 6](#fig6){ref-type="fig"}*D*), which were reduced significantly upon MB treatment ([Figure 8](#fig8){ref-type="fig"}*C*). Clearly, such increased bile salt synthesis may be a further detrimental impact in HCD-fed *Atp7b*^*-/-*^ rat livers because accumulating bile salts are hepatotoxic (especially to hepatic mitochondria).[@bib46], [@bib47]

In conclusion, the combination of accumulating copper with an HCD is highly detrimental to hepatic mitochondria. A toxic triad of ATP depletion, massively increased ROS, and bile salts seals the fate of affected hepatocytes. This indicates that a high- vs normal-calorie nutrition may have a tremendous impact on WD progression and severity and may contribute to the striking phenotype--genotype discrepancies encountered in WD patients, in agreement with a recent review article that indicated the importance of lifestyle modifications in WD.[@bib18] We therefore suggest monitoring such aspects of nutrition in much more detail in the future, to establish whether dietary counseling of WD patients may be of therapeutic benefit.

Materials and Methods {#sec3}
=====================

Animal Studies {#sec3.1}
--------------

Animals were maintained under the Guidelines for the Care and Use of Laboratory Animals of the Helmholtz Center Munich. Animal experiments were approved by the government authorities of the Regierung von Oberbayern, Munich, Germany.

Control *Atp7b*^*+/-*^ and WD *Atp7b*^*-/-*^ rats of both sexes ([Table 2](#tbl2){ref-type="table"}; strain name, LPP crossbreed between Long Evans cinnamon rats and Piebald Virol Glaxo rats; bred in-house, provided by Borjigin) were used because we currently have no indication for a sex-dependent altered WD phenotype in these animals.[@bib3] Animals were fed ad libitum either on an ND (1314; Altromin Spezialfutter GmbH, Seelenkamp, Germany; copper content, 13.9 mg/kg; metabolic energy, 3301 kcal/kg; 14% kcal from fat) and tap water (copper content, \<0.2 mg/L) or on an HCD (Altromin Spezialfutter GmbH; copper content, 9.3 mg/kg; metabolic energy, 4523 kcal/kg; 45% kcal from fat) and fructose syrup (metabolic energy, 722 kcal/L) in drinking water supplemented with 3.1 mg/L copper.[@bib14], [@bib24] Rats were fed an HCD starting at an age of 46--50 days until an age of 79--82 days. To additionally test for a difference in the age of onset and rate of liver damage progression on the 2 diets (HCD vs ND), a subset of animals was analyzed in parallel at an age of 67, 73, and 75 days ([Table 2](#tbl2){ref-type="table"}). Daily consumption values for rats were estimated from the literature to be approximately 20 g chow and 30 mL water, respectively.[@bib48] In subsequent control measurements in *Atp7b*^*+/-*^ rats, we determined an average uptake of 16.1 ± 1.7 g ND food and 31 ± 3 mL water per day (ie, approximately 230 μg copper/day), and 12.5 ± 1.7 g HCD food and 50 ± 15 mL fructose syrup (ie, approximately 272 μg copper/day). Thus, the HCD/sugar-water diet supplied slightly more copper (approximately 18%) compared with the ND/tap water diet, but nevertheless resulted in almost equal liver homogenate copper contents in both *Atp7b*^*+/-*^ rats and *Atp7b*^*-/-*^ rats ([Figure 3](#fig3){ref-type="fig"}*C*). MB treatment of HCD-fed *Atp7b*^*-/-*^ rats was performed once daily for 5 consecutive days starting at an age of 74--75 days, as recently described (150 mg/kg body weight intraperitoneally).[@bib5]

Chemicals {#sec3.2}
---------

Chemicals were mostly obtained from Sigma--Aldrich (Taufkirchen, Germany). Nitric acid, K~2~HPO~4,~ KCl, malate, iodacetamide, multi-element standard IV, copper (II) sulfate pentahydrate, ethanol, and xylene were purchased from Merck (Darmstadt, Germany). Acetyl-CoA, reduced nicotinamide adenine dinucleotide (NADH), phosphoenolpyruvate, pyruvate kinase and lactate dehydrogenase were obtained from Roche Diagnostics (Mannheim, Germany). Bovine serum albumin (BSA) and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) were purchased from Carl-Roth (Karlsruhe, Germany). Tris-(hydroxymethyl)aminomethane (TRIS) was obtained from VWR International GmbH (Ismaning, Germany). Gelatin was purchased from Grüssing (Filsum, Germany). Rhodium Inductively Coupled Plasma (ICP) standard solution was purchased from SCP Science (Baie D'Urfé, Canada). Osmium tetroxide and uranyl-less contrasting agent were obtained from Science Services GmbH (Munich, Germany). Propylene oxide and epoxy resin were purchased from SERVA Electrophoresis GmbH (Heidelberg, Germany). Lead citrate was purchased from Leica Biosystems (Wetzlar, Germany).

Liver Examination {#sec3.3}
-----------------

Serum AST and bilirubin levels were measured with the Reflotron system (Roche Diagnostics, Penzberg, Germany) and liver damage in animals was considered clinically apparent if the serum AST level was greater than 200 U/L and/or the bilirubin level was greater than 0.5 mg/dL.[@bib5] Serum cholesterol nonesterified fatty acids and serum triglycerides were analyzed with Respons910 (Diasys Greiner GmbH, Flacht, Germany) according to the manufacturer\'s guidelines. Serum ceruloplasmin activity was measured as described elsewhere.[@bib49], [@bib50] Total serum bile salt concentrations were quantified in serum samples using the Diazyme total bile salt kit (Diazyme Laboratrories, Poway, CA) according to the manufacturer's instructions. Histologic evaluation was performed on formalin-fixed, paraffin-embedded H&E-stained liver samples. Morphologic features were summarized as an activity score as recommended for the diagnosis of steatohepatitis in NAFLD (NAS)[@bib25] as well as for hepatitis (HAI score).[@bib51] For quantification of liver triglycerides, 100 mg/mL liver tissue was sonicated within 5% NP40 solution, heated for 5 minutes at 96°C, and cooled on ice. Homogenates were cleared for 2 minutes at 20,000×*g*, and supernatants (diluted in 5% NP40 solution 1:1--1:10 as required) were analyzed with Respons910 (Diasys Greiner GmbH).[@bib13]

Metal Content Determination {#sec3.4}
---------------------------

Copper in serum, liver homogenate, cytosol, and mitochondria, as well as kidney homogenate, were analyzed by ICP Optical Emission Spectrometry (Ciros Vision, SPECTRO Analytical Instruments GmbH, Kleve, Germany) after wet ashing of samples with 65% nitric acid.[@bib4]

Preparation of Rat Liver Cytosol and Mitochondria {#sec3.5}
-------------------------------------------------

Freshly removed liver tissue was homogenized with a Teflon-glass homogenizer (B. Braun Biotech, Melsungen, Germany) in isolation buffer (pH 7.2) containing 300 mmol/L sucrose, 5 mmol/L 2-\[(2-hydroxy-1,1-bis(hydroxymethyl)ethyl)amino\]ethanesulfonic acid (TES), 0.2 mmol/L ethylene glycol-bis(β-aminoethyl ether)-*N,N,N′,N′*-tetraacetic acid (EGTA), and 0.1% BSA. Approximately 1 mL of the homogenate was centrifuged at 100,000×*g* (1 h, 4°C), and the supernatant (liver cytosol) was collected and stored at -80°C.

For mitochondrial isolation, the remaining homogenate was cleared from debris and nuclei by an 800×*g* (10 min at 4°C) centrifugation step, and a crude mitochondrial fraction was pelleted at 18,900×*g* (20 min at 4°C). To purify mitochondria, the pellet was suspended in isolation buffer, loaded on a Nycodenz gradient (Axis-Shield PoC, Oslo, Norway; gradient composition was as follows: 1 mL of 40%, 1 mL of 33%, 3 mL of 28%, 2 mL of 27%, 2 mL of 24% Nycodenz solution; diluted in 10 mmol/L TRIS, pH 7.4), and centrifuged at 74,100×*g* (1 h, 4°C). The mitochondrial fraction (layer at the 28% gradient phase) was collected and suspended in isolation buffer without BSA and washed 2 times at 18,900×*g* (10 min at 4°C).[@bib52], [@bib53], [@bib54]

Mitochondrial ATP Production {#sec3.6}
----------------------------

ATP production was determined using the ATP Bioluminescence Assay Kit (Roche Diagnostics, Mannheim, Germany) according to the manufacturer\'s guideline. In detail, 10 μg mitochondria were incubated with 160 μmol/L adenosine diphosphate (ADP) and 5 mmol/L succinate for 30 minutes at room temperature in a buffer containing 0.2 mol/L sucrose, 10 mmol/L 3-(N-morpholino)propanesulfonic acid-TRIS, 1 mmol/L inorganic phosphate, 10 μmol/L EGTA and 2 μmol/L rotenone. As background control, potassium cyanide (2 mmol/L, respiratory chain complex IV inhibitor) was added. Mitochondrial ATP production was calculated in pmol/min/mg protein based on background-corrected luminescence signals and ATP standard curves (Roche Diagnostics, Mannheim, Germany).

Mitochondrial Respiration {#sec3.7}
-------------------------

Mitochondrial respiration was measured with an Oxygraph-2k instrument and processed via DatLab 6.2 software (Oroboros Instruments, Innsbruck, Austria). Per each chamber, 100 μg mitochondria was supplied in a buffer containing 0.25 mol/L sucrose, 1 mmol/L EGTA, 30 mmol/L K~2~HPO~4~, 15 mmol/L KCl, 5 mmol/L MgCl~2~, 25 mmol/L succinate, 1 μmol/L rotenone, and 0.5 mmol/L ADP, and oxygen consumption rates were measured as succinate-linked phosphorylation. To determine leak respiration, 2.5 mmol/L oligomycin was added (final, 2.5 μmol/L) to block ATP synthase. Subsequently, the protonophore carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone was titrated (2 μL steps from a 20 μmol/L stock solution) to induce maximum oxygen consumption (electron transfer system capacity). The respiratory control ratio was calculated by dividing the succinate-linked phosphorylation oxygen consumption by the oxygen consumption upon oligomycin addition.

Mitochondrial H~2~O~2~ Production {#sec3.8}
---------------------------------

Mitochondrial H~2~O~2~ production was analyzed after resorufin fluorescence[@bib55] (converted from Amplex Red; Molecular Probes, Invitrogen, Karlsruhe, Germany) at λ~Ex.~ 540/20 nm and λ~Em.~ 620/40 nm. The assay was performed with 75 μg mitochondria in 150 μL buffer (pH 7.4) containing 125 mmol/L KCl, 10 mmol/L 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 5 mmol/L MgCl~2~, 2 mmol/L K~2~HPO~4~, 5 μmol/L MnCl~2~, and as substrates either 10 mmol/L succinate/2 μmol/L rotenone and 3.2 mmol/L ADP, or 5 mmol/L glutamate/5 mmol/L malate. To start the reaction, 50 μL of a solution containing 320 μmol/L Amplex Red, 2 U/mL horseradish peroxidase, and 60 U/mL superoxide dismutase was added. Resorufin fluorescence was followed up in a plate reader (Synergy 2; BioTek Instruments, Inc, Bad Friedrichshall, Germany) and the Resorufin slope was converted into the rate of H~2~O~2~ production in pmol/min/mg with a H~2~O~2~ standard curve.[@bib55]

F~1~F~O~-Activity and Citrate Synthase Activity {#sec3.9}
-----------------------------------------------

F~1~F~O~ activity was assessed as described before.[@bib13], [@bib56] In detail, 20 μg mitochondria were incubated in buffer containing either 50 mmol/L TRIS (pH 8.0) or an additional 3 μmol/L oligomycin (F~1~Fo inhibitor, negative control) for 5 minutes at 37°C in a plate reader (Synergy 2). To start the reaction, a final mixture of 0.5 mmol/L ATP, 3 μmol/L carbonyl cyanide 3-chlorophenylhydrazone, 1 mg/mL BSA, 1 μmol/L antimycin A, 10 mmol/L KCl, 4 mmol/L MgCl~2~, 0.2 mmol/L NADH, 2 mmol/L phosphoenolpyruvate, 4 U lactate dehydrogenase, and pyruvate kinase were added. The F~1~F~O~ activity was determined in the reverse direction after ATP hydrolysis and NADH oxidation in parallel to the conversion of pyruvate to lactate. The decrease in NADH absorbance at 340 nm was proportional to the ATPase activity and was calculated in nmol/min/mg protein. The F~1~F~O~ activity was normalized to the activity of the housekeeping enzyme citrate synthase (CS). The activity of mitochondrial CS was determined according to earlier reports.[@bib57], [@bib58] In brief, 280 μL of a solution containing 2.5% (wt/vol) Triton X-100, 100 μmol/L 5,5'-dithiobis-(2-nitrobenzoic acid), 75 μg acetyl-CoA, and 500 μmol/L oxaloacetate was incubated at 37°C. The reaction was started by adding 20 μg mitochondria and followed at 412 nm for 5 minutes. CS activities were calculated from the linear slopes of the initial rates.[@bib56]

Electron Microscopy {#sec3.10}
-------------------

Animal livers and isolated mitochondria were fixed with 2.5% glutaraldehyde (Science Services GmbH), postfixed with 1% osmium tetroxide, dehydrated with ethanol and propylene oxide, and were embedded in epoxy resin. Sixty-nanometer sections were cut using the Leica EM UC7 microtome (Leica Biosystems) or the Reichert-Jung Ultracut E microtome (now Leica Biosystems). Ultrathin sections were negative-stained with uranyl acetate (Uranyless) and lead citrate. Images were acquired using either a FEI Tecnai-12 electron microscope equipped with a VELETTA CCD digital camera (FEI, Eindhoven, The Netherlands) or using a Jeol 1200 EXII electron microscope (Akishima, Tokyo, Japan) equipped with a KeenViewII digital camera (Olympus, Hamburg, Germany) and processed with the iTEM software package (anlySISFive; Olympus).

For structural analyses, mitochondria were grouped in normally structured mitochondria of the "condensed type"[@bib59] or in altered mitochondria with marked membrane detachments, matrix condensations, and ballooned cristae. A total of 350--750 mitochondria were included per group of animals.

Proteome Analysis {#sec3.11}
-----------------

### Mass spectrometry (MS) sample preparation {#sec3.11.1}

Liver homogenates were lysed in urea buffer (9 mol/L urea, 6 mol/L thiourea, 65 mmol/L dithiothreitol). A total of 10 μg protein per replicate was proteolytically cleaved by applying a modified filter-aided sample preparation procedure,[@bib14] including a quenching step using 1 mol/L dithiothreitol to bind unreacted iodacetamide. After elution of peptides, samples were acidified with 0.5% trifluoroacetic acid and analyzed on the OrbitrapXL (Thermo Fisher Scientific, Dreieich, Germany) as described.[@bib14], [@bib60]

### Mass spectrometry {#sec3.11.2}

Liquid chromatography tandem-mass spectrometry analysis was performed on a LTQ-Orbitrap XL operated on a nano-high-performance liquid chromatography (UltiMate 3000 RSLCnano System; Thermo Fisher Scientific) as described elsewhere,[@bib14], [@bib61] with the modification of using a nonlinear 300-minute liquid chromatography gradient.

### Protein identification and label-free relative quantification {#sec3.11.3}

Acquired spectra were analyzed using Progenesis QI for proteomics (v2.0; Nonlinear Dynamics, Newcastle upon Tyne, UK), as described previously,[@bib14] with the following adaptations: spectra were searched using the search engine Mascot (version 2.5.1; Matrix Science, London, UK) against the Ensembl rat database (release 80; 28,609 sequences). The Mascot-integrated decoy database search using the Percolator algorithm was set to a peptide false discovery rate of less than 1.5%. Peptide assignments were imported into Progenesis QI. Normalized abundances of peptides were summed up and allocated to the respective protein.

Laser Ablation ICP-Mass Spectrometry {#sec3.12}
------------------------------------

For laser ablation ICP-MS analysis, tissue sections of rat liver samples embedded in paraffin were prepared with a thickness of 5 μm using a microtome HM 355S (Thermo Scientific, Bremen, Germany). To quantify the copper concentration in the tissue samples, matrix-matched standards based on 10% gelatin in aqueous solutions of copper (II) sulfate pentahydrate were prepared as described before.[@bib62] The concentration range for copper was between 10 and 1000 μg/g. To validate the standard concentrations, bulk analysis after digestion with nitric acid was used as described before.[@bib62] A laser ablation system (LSX-213 G2+; Teledyne CETAC Technologies, Omaha, NE) was used. ICP-MS detection was performed with a quadrupole-based iCAP TQ (Thermo Fisher Scientific). The laser ablation and ICP-MS were connected with Tygon tubing Saint-Gobain (Courbevoie, France). The following ICP-MS parameters were applied for all measurements: forward power, 1550 W; cool gas flow, 14 L/min; and auxiliary gas flow, 0.8 L/min. In-house--developed software was used to convert the laser ablation ICP-MS data into 2-dimensional images. The copper concentration was calculated using a linear calibration function derived from the average signal intensities for each standard using Microsoft Excel 2016 (Microsoft Corp, Redmond, WA).

Miscellaneous {#sec3.13}
-------------

MB was isolated from the spent media of *Methylosinus trichosporium* OB3b as previously described.[@bib63] Protein quantification was performed by the Bradford[@bib64] or Biuret assay (T1949; Sigma-Aldrich).

Statistics {#sec3.14}
----------

Throughout this study, N refers to the number of analyzed animals. Data are presented as means ± SD. Statistical significance was analyzed using 1-way analysis of variance with the Tukey multiple comparisons test, or the nonparametric Kruskal--Wallis test when comparing 3 or more sample sets (GraphPad Prism 7, GraphPad Software, Inc, San Diego, CA). For 2 group comparisons, the unpaired 2-tailed Student *t* test was used for parametric data and the Mann--Whitney test was used for nonparametric data, respectively (GraphPad Prism 7).
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[^1]: Authors share co-first authorship.

[^2]: Authors share co-senior authorship.

[^3]: F, female; M, male.

[^4]: Animals are considered as having clinically apparent WD if AST level is greater than 200 U/L and/or bilirubin level is greater than 0.5 mg/dL.

[^5]: NOTE. Data are presented as mean ratios from 3 age-matched animals (age, 80--82 days).

[^6]: ER, endoplasmic reticulum.

[^7]: Fold-changes greater than 2 compared with +/-ND control.

[^8]: Fold-changes between 1.5 and 2.0 compared with +/-ND control.

[^9]: NOTE. Data are presented as mean ratios from 3 age-matched animals (age, 80--82 days).

[^10]: ER, endoplasmic reticulum.

[^11]: Fold-changes greater than 2 compared with +/-ND control.

[^12]: Fold-changes between 1.5 and 2.0 compared with +/-ND control.

[^13]: NOTE. Data are presented as mean ratios from 3 age-matched animals (age, 80--82 days).

[^14]: ER, endoplasmic reticulum.

[^15]: Fold-changes greater than 2 compared with +/- ND control.

[^16]: Fold-changes between 1.5 and 2.0 compared with +/- ND control.

[^17]: NOTE. Data are presented as mean ratios from 3 age-matched animals (age, 80--82 days).

[^18]: ER, endoplasmic reticulum.

[^19]: Fold-changes greater than 2 compared with +/- ND control.

[^20]: Fold-changes between 1.5 and 2.0 compared with +/- ND control.

[^21]: NOTE. Data on AST, bilirubin, and body weight are present before and after 5 days of MB treatment. NAFLD activity score was as follows: ≤2, no nonalcoholic steatohepatitis; 3--4, borderline nonalcoholic steatohepatitis; ≥5 definite nonalcoholic steatohepatitis.

[^22]: Cu, copper; nd, not determined.

[^23]: Values are shown as medians.

[^24]: Mitochondrial copper depletion relative to the mean mitochondrial copper value of female untreated *Atp7b^-/-^* rats.
